| 1 |
33961299 | Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. | 2022 Feb |
4 |
| 2 |
35247279 | Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin. | 2022 Mar 5 |
6 |
| 3 |
24746233 | The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. | 2014 Jun |
1 |
| 4 |
23137182 | Saxagliptin overview: special focus on safety and adverse effects. | 2013 Jan |
1 |
| 5 |
22496391 | Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. | 2012 Jul |
1 |
| 6 |
21651615 | Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. | 2011 Jul |
1 |
| 7 |
22287853 | Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. | 2011 |
3 |
| 8 |
20590741 | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. | 2010 Aug |
1 |
| 9 |
20690781 | Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. | 2010 Sep |
3 |